ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 218

Accuracy of Humasens-Plus Point-of-Care Uric Acid Meter Using Capillary Blood Obtained By Fingertip Puncture

Stephanie Fabre1, Jean-Marie Launay1, Jean-François Gautier1, Adam Platt2, Jeffrey N. Miner3, Glen Hughes2, Pascal Richette4 and Thomas Bardin1, 1Hôpital Lariboisière, Paris, France, 2AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 3Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, 4Fédération de Rhumatologie, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Diagnostic Tests, gout, measure, test and uric acid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  A key factor in the success of gout management is the long-term lowering of serum uric acid (sUA) levels below predetermined targets (5 or 6 mg/dL). Monitoring of uricemia in gout patients is therefore important, especially during drug titration, and is presently done in the laboratory on serum samples obtained after venous puncture. An accurate sUA meter that would allow rapid testing by the health care professionals and self-measurement of uric acid by the gouty patient should improve patient monitoring and management of gout. This study aimed to assess the reliability of immediate uricemia measurement in capillary blood samples obtained from fingertip puncture using the HumaSens-plus point-of-care meter compared with that of a standard laboratory assay.

Methods:  Finger-prick blood sUA levels were measured from 238 consenting diabetic patients using the commercially available HumaSens-plus sUA meter (European Conformity marked and approved for EU market use only). Each patient also had a venous sample taken and prepared as Li-Heparin plasma for analysis in the biochemistry laboratory using a uricase automated colorimetric assay. Since the sUA meter has a dynamic range of 3–20 mg/dL, a subject’s capillary reading was excluded from statistical analysis when the meter read LO or HI, indicating that the subject’s sUA value was lower than or higher than the calibrated range. Statistical analysis included calculation of the Pearson’s correlation coefficient (PCC) between the 2 measured values and Bland-Altman graphic representations of means and differences between the 2 measurement results. A total of 206 paired measurements were calculated to be necessary for calculation of a PCC of 80% with a precision of 0.10 and an alpha risk of 0.05%.

Results: Eighteen capillary samples were marked LO by the meter: 15 were confirmed by standard biochemistry to be below 3 mg/dL, and 3 were above (3.2, 3.4, and 7.1 mg/dL). Two capillary samples were read HI and were measured at 5.1 and 3.6 mg/dL by biochemistry. In the remaining 218 samples, PCC was 0.92, and Bland-Altman curve showed acceptable agreement all over the tested values, with the following limits of agreement: [-1.1 mg/dL; 1.39 mg/dL]. On average, plasma measurements were 1.03-fold higher than capillary measurements. Accuracy was 92.7% at the 20% margin. Predictive value was 77.1% for a capillary measurement found to be above the target (6 mg/dL) by biochemistry measurement. For capillary measurement found to be below the target by biochemistry measurement, predictive value was 92.7%.

Conclusion:  HumaSens meters were easy to use, and these preliminary results showed that the meters give results that are reasonably comparable to those of the laboratory assay; as a result, they may be useful in the clinic and in epidemiologic studies. Further studies are underway to better understand discrepancies between the two techniques by looking at drug intakes and other biochemical and hematologic parameters measured in these patients, as well as by comparing results of both techniques to liquid chromatography-mass spectrometry reference measurements.


Disclosure: S. Fabre, None; J. M. Launay, None; J. F. Gautier, None; A. Platt, AstraZeneca, 3; J. N. Miner, Ardea Biosciences, Inc., a member of the AstraZeneca Group, 3; G. Hughes, AstraZeneca, 3; P. Richette, Algorithm, Astellas, AstraZeneca, Ipsen, Menarini, Novartis, Savient, Takeda, 8,Ipsen, Menarini, 2,AstraZeneca, Biomex, Ipsen, Menarini, Novartis, Savient, Sobi, 5; T. Bardin, None.

To cite this abstract in AMA style:

Fabre S, Launay JM, Gautier JF, Platt A, Miner JN, Hughes G, Richette P, Bardin T. Accuracy of Humasens-Plus Point-of-Care Uric Acid Meter Using Capillary Blood Obtained By Fingertip Puncture [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/accuracy-of-humasens-plus-point-of-care-uric-acid-meter-using-capillary-blood-obtained-by-fingertip-puncture/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/accuracy-of-humasens-plus-point-of-care-uric-acid-meter-using-capillary-blood-obtained-by-fingertip-puncture/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology